Natera Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  11407.9

• Ticker

  NTRA.O

• ISIN

  US6323071042

• IPO date

  2015-07-02

• Availability on Russian exchanges

  Yes

• Reporting for

  2024-02-29

• Date fact. publication of reports

  2023-12-31

Natera, Inc. is a diagnostics company. The Company is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free DNA (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.